Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy.
GH excess is characterized by alterations of body composition such as decreased body fat mass; however, scant data are present regarding its effect on serum leptin levels. To better elucidate this topic, leptin secretion was studied in 20 acromegalic patients, before and after 6 months of treatment with somatostatin analogs (SR-lanreotide 30 mg and octreotide LAR). Basal GH, IGF-I, insulin, blood glucose and lipid levels were measured and the area under the curve (AUC) for insulin and glucose and oral glucose insulin sensitivity (OGIS) during oral glucose tolerance test (OGTT) were calculated. After 6 months of somatostatin analogs therapy, a significant reduction in GH and IGF-I plasma levels was observed (p<0.0005, both) with a significant increase of leptin levels (7.4+/-1.3 vs 13.2+/-1.6 ng/ml; p<0.05). Interestingly, the typical correlation of leptin with body mass index (BMI) was not present in active acromegaly, whereas it was restored after somatostatin analogs treatment; moreover, the gender difference in leptin secretion between men and women was preserved in active and controlled acromegaly. In conclusion, the gender-based leptin differences are preserved and leptin secretion/BMI ratio is normalized in acromegalic patients after somatostatin analogs therapy.
Baldelli
R
R
Department of Clinical Sciences, Endocrinology Section, First School of Medicine, University of Rome La Sapienza, Rome, Italy. baldelli@katamail.com
Durante
C
C
D'Amico
E
E
Diacono
F
F
Tamburrano
G
G
Casanueva
F F
FF
D000172:Acromegaly / Q000097:blood* / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D003692:Delayed-Action Preparations; D005260:Female; D019382:Human Growth Hormone / Q000097:blood; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D020738:Leptin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage*; D010456:Peptides, Cyclic / Q000008:administration & dosage*; D012727:Sex Characteristics; D013004:Somatostatin / Q000008:administration & dosage* / Q000031:analogs & derivatives; D016896:Treatment Outcome
D003692:Delayed-Action Preparations; D020738:Leptin; D010456:Peptides, Cyclic; C060347:lanreotide; D019382:Human Growth Hormone; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D015282:Octreotide